Lhotova Klara, Stolarova Lenka, Zemankova Petra, Vocka Michal, Janatova Marketa, Borecka Marianna, Cerna Marta, Jelinkova Sandra, Kral Jan, Volkova Zuzana, Urbanova Marketa, Kleiblova Petra, Machackova Eva, Foretova Lenka, Hazova Jana, Vasickova Petra, Lhota Filip, Koudova Monika, Cerna Leona, Tavandzis Spiros, Indrakova Jana, Hruskova Lucie, Kosarova Marcela, Vrtel Radek, Stranecky Viktor, Kmoch Stanislav, Zikan Michal, Macurek Libor, Kleibl Zdenek, Soukupova Jana
Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
Cancers (Basel). 2020 Apr 13;12(4):956. doi: 10.3390/cancers12040956.
Ovarian cancer (OC) is the deadliest gynecologic malignancy with a substantial proportion of hereditary cases and a frequent association with breast cancer (BC). Genetic testing facilitates treatment and preventive strategies reducing OC mortality in mutation carriers. However, the prevalence of germline mutations varies among populations and many rarely mutated OC predisposition genes remain to be identified. We aimed to analyze 219 genes in 1333 Czech OC patients and 2278 population-matched controls using next-generation sequencing. We revealed germline mutations in 18 OC/BC predisposition genes in 32.0% of patients and in 2.5% of controls. Mutations in , , , and mismatch repair genes conferred high OC risk (OR > 5). Mutations in and were associated with moderate risk (both OR = 3.5). mutations dominated in almost all clinicopathological subgroups including sporadic borderline tumors of ovary (BTO). Analysis of remaining 201 genes revealed somatic mosaics in and germline mutations in and associating with a high/moderate OC risk significantly; however, further studies are warranted to delineate their contribution to OC development in other populations. Our findings demonstrate the high proportion of patients with hereditary OC in Slavic population justifying genetic testing in all patients with OC, including BTO.
卵巢癌(OC)是最致命的妇科恶性肿瘤,其中很大一部分为遗传性病例,且常与乳腺癌(BC)相关。基因检测有助于制定治疗和预防策略,降低突变携带者的OC死亡率。然而,种系突变的患病率在不同人群中有所不同,许多很少发生突变的OC易感基因仍有待确定。我们旨在使用下一代测序技术分析1333例捷克OC患者和2278例人群匹配对照中的219个基因。我们在32.0%的患者和2.5%的对照中发现了18个OC/BC易感基因的种系突变。 、 、 以及错配修复基因的突变赋予了较高的OC风险(OR>5)。 和 的突变与中度风险相关(两者OR均=3.5)。 突变在几乎所有临床病理亚组中占主导地位,包括散发性卵巢交界性肿瘤(BTO)。对其余201个基因的分析显示, 存在体细胞镶嵌现象, 以及 存在种系突变,与高/中度OC风险显著相关;然而,需要进一步研究来阐明它们在其他人群中对OC发生发展的作用。我们的研究结果表明,斯拉夫人群中遗传性OC患者的比例很高,这证明对所有OC患者,包括BTO患者进行基因检测是合理的。